ENDRA Life Sciences Inc (NDRA)vsWaters Corporation (WAT)
NDRA
ENDRA Life Sciences Inc
$3.75
+8.38%
HEALTHCARE · Cap: $4.06M
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
Smart Verdict
WallStSmart Research — data-driven comparison
WAT leads profitability with a 20.3% profit margin vs 0.0%. NDRA trades at a lower P/E of 0.2x. WAT earns a higher WallStSmart Score of 60/100 (C).
NDRA
Avoid17
out of 100
Grade: F
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+97.3%
Fair Value
$132.74
Current Price
$3.75
$128.99 discount
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
Trading at 17.0x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NDRA
The strongest argument for NDRA centers on P/E Ratio.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : NDRA
The primary concerns for NDRA are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 3.07 is elevated, increasing financial risk.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
NDRA profiles as a value stock while WAT is a mature play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 6.8% — sustainability is the question.
WAT generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (60/100 vs 17/100), backed by strong 20.3% margins. NDRA offers better value entry with a 97.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ENDRA Life Sciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?